Inventor · disambiguated record
John Parkinson
Also filed as: PARKINSON JOHN · PARKINSON JOHN F
19 granted patents·10 pending applications·207 citations·filing 1999–2024
94Inventor score
Files withBERLEX LAB8CELTAXSYS INC4BAYER SCHERING PHARMA AG3CELLTAXIS LLC3THETIS PHARMACEUTICALS LLC3
Top patents by PatentIndex Score
29 records- 0194US6432947B1N-heterocyclic derivatives as NOS inhibitorsBERLEX LAB·Filed 1999·Granted Aug 13, 2002·89 cites·34 claims
- 0292US9315509B2Diamine derivatives as inhibitors of leukotriene A4 hydrolaseCELTAXSYS INC·Filed 2014·Granted Apr 19, 2016·17 cites·20 claims
- 0392US7737145B2Diamine derivatives as inhibitors of leukotriene A4 hydrolaseESTRELLITA PHARMACEUTICALS LLC·Filed 2006·Granted Jun 15, 2010·32 cites·10 claims
- 0490US11267819B2Diamine derivatives as inhibitors of leukotriene A4 hydrolaseCELLTAXIS LLC·Filed 2020·Granted Mar 8, 2022·2 cites·21 claims
- 0590US8569303B2Diamine derivatives as inhibitors of leukotriene A4 hydrolaseARNAIZ DAMIAN O·Filed 2010·Granted Oct 29, 2013·19 cites·12 claims
- 0688US2025296935A1Diamine Derivatives as Inhibitors of Leukotriene A4 HydrolaseCELLTAXIS LLC·Filed 2024·Application pending·0 cites
- 0784US6831186B2Lipoxin A4 analogsSCHERING AKTIENGESELLSCHFT·Filed 2002·Granted Dec 14, 2004·26 cites·17 claims
- 0881US12173009B2Diamine derivatives as inhibitors of leukotriene A4 hydrolaseCELLTAXIS LLC·Filed 2022·Granted Dec 24, 2024·0 cites·23 claims
- 0978US6747031B2N-heterocyclic derivatives as NOS inhibitorsBERLEX LAB·Filed 2002·Granted Jun 8, 2004·6 cites·10 claims
- 1077US7223798B2Lipoxin A4 analogsSCHERING AG·Filed 2004·Granted May 29, 2007·8 cites·20 claims
- 1173US6670473B2N-heterocyclic derivatives as NOS inhibitorsBERLEX LAB·Filed 2002·Granted Dec 30, 2003·3 cites·8 claims
- 1270US6841674B2N-heterocyclic derivatives as NOS inhibitorsBERLEX LAB·Filed 2002·Granted Jan 11, 2005·2 cites·6 claims
- 1369US2024156909A1Compositions and methods for cancer therapyTHETIS PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 1466US6887865B2N-heterocyclic derivatives as NOS inhibitorsPHARMACOPEIA DRUG DISCOVERY·Filed 2002·Granted May 3, 2005·1 cites·8 claims
- 1566US6849739B2N-heterocyclic derivatives as NOS inhibitorsBERLEX LAB·Filed 2002·Granted Feb 1, 2005·1 cites·2 claims
- 1666US6846829B2N-heterocyclic derivatives as NOS inhibitorsBERLEX LAB·Filed 2002·Granted Jan 25, 2005·1 cites·18 claims
- 1765US11986512B2Compositions and methods for cancer therapyTHETIS PHARMACEUTICALS LLC·Filed 2022·Granted May 21, 2024·0 cites·44 claims
- 1865US2018230159A1Diamine derivatives as inhibitors of leukotriene a4 hydrolaseCELTAXSYS INC·Filed 2018·Application pending·0 cites
- 1961US7928255B2Intermediates for the preparation of lipoxin A4 analogsBAYER SCHERING PHARMA AG·Filed 2006·Granted Apr 19, 2011·0 cites·6 claims
- 2061US2013123243A1Diamine derivatives as inhibitors of leukotriene a4 hydrolaseCELTAXSYS INC·Filed 2012·Application pending·0 cites
- 2161US2024180859A1Compositions and methods for immune-mediated inflammatory diseasesTHETIS PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 2260US2016272649A1Diamine derivatives as inhibitors of leukotriene a4 hydrolaseCELTAXSYS INC·Filed 2016·Application pending·0 cites
- 2355US6864263B2N-heterocyclic derivatives as NOS inhibitorsBERLEX LAB·Filed 2002·Granted Mar 8, 2005·0 cites·11 claims
- 2455US6841673B2N-heterocyclic derivatives as nos inhibitorsBERLEX LAB·Filed 2002·Granted Jan 11, 2005·0 cites·1 claims
- 2549US6864368B2N-heterocyclic derivatives as NOS inhibitorsBERLAX LAB INC·Filed 2002·Granted Mar 8, 2005·0 cites·1 claims
- 2646US2007179094A1Modulation of MDL-1 activity for treatment of inflammatory diseaseBAYER SCHERING PHARMA AG·Filed 2007·Application pending·0 cites
- 2746US2008119439A1Treatment and prevention of intestinal fibrosisBAYER SCHERING PHARMA AG·Filed 2007·Application pending·0 cites
- 2842US2007155727A1Amide inhibitors of leukotriene A4 hydrolaseSCHERING AKTIENGESSELLSCHAFT·Filed 2006·Application pending·0 cites
- 2940US2004096881A1eNOS mutants useful for gene therapySCHERING AG·Filed 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →